Search

Your search keyword '"Alguel, Hana"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Alguel, Hana" Remove constraint Author: "Alguel, Hana"
81 results on '"Alguel, Hana"'

Search Results

1. HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx

2. Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

4. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53

6. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes

7. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

8. Targeting the Immune System in Pancreatic Cancer

9. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer

10. Variants That Affect Function of Calcium Channel TRPV6 Are Associated With Early-Onset Chronic Pancreatitis

11. KRas, in addition to Tp53 is a driver for early carcinogenesis and a molecular target in a mouse model of invasive gastro-esophageal adenocarcinoma

12. Targeting nNOS ameliorates the severe neuropathic pain due to chronic pancreatitis

13. Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice

18. Loss of P53 Function Activates JAK2–STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival

22. Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic

24. Impaired Autophagy Induces Chronic Atrophic Pancreatitis in Mice via Sex- and Nutrition-Dependent Processes

34. Phenotype screens of genetically engineered mouse models of pancreatic cancer identify a Tgfa-Ccl2-paxillin axis driving human-like perineural invasion

35. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

37. POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).

40. Induction Chemotherapy in Locally Advanced Pancreatic Cancer (LAPC) - Final Results of a Multicenter Randomized Phase 2 AIO Trial (NEOLAP)

42. CD36-triggered cell invasion and persistent tissue colonization by tumor microvesicles during metastasis

43. A blood-based assay for diagnosis of early-stage pancreatic cancer.

44. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: The RAMIRIS study.

45. Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP).

46. Distinct Pathogenesis of Pancreatic Cancer Microvesicle-Associated Venous Thrombosis Identifies New Antithrombotic Targets In Vivo

47. Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP).

48. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage

49. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Catalog

Books, media, physical & digital resources